Experimental drug ampligen takes on pancreatic cancer in new trial

NCT ID NCT05494697

Terminated Disease control Sponsor: AIM ImmunoTech Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the experimental drug Ampligen to standard care can help people with locally advanced pancreatic cancer that hasn't spread. About 90 participants who have completed at least four months of initial chemotherapy will receive either Ampligen plus standard care or standard care alone. The main goal is to see if the combination delays tumor growth and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ampligen (rintatolimod)
What this could lead to: If successful, this could provide a new treatment option to help control locally advanced pancreatic cancer and extend survival when used after initial therapy.
What could go wrong: This is an early-phase trial with only 90 participants, and the study is currently suspended. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Virginia Mason Medical Center

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.